Locations:
SearchAdvertisement
Findings support need for personalized disease management
Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy
The decision to use 223-radium, and an outcome that exceeded expectations
Tumor genomics offer clues for identifying high risk of relapse
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
High-quality programs help ensure that screening – now considered standard of care – is done right
Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients
Study to test efficacy of immunotherapy with chemotherapy and radiation
Molecular targets may offer noncytotoxic treatment path
The cornerstone of a successful doctor-patient relationship
The rationale and promise of a new method to enable chemotherapy delivery
Advertisement
Advertisement